Eli Lilly's Strategic Moves to Address Patent Cliff Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy LLY?
Source: Fool
- GLP-1 Market Performance: Eli Lilly, as the leading manufacturer of GLP-1 drugs, has seen a 225% stock price increase over the past three years, yet its price-to-earnings ratio has soared to 49, with a meager 0.6% dividend yield, indicating market over-optimism regarding short-term performance.
- Sales Growth and Dependency: In 2025, sales of Mounjaro and Zepbound surged by 99% and 175% respectively, but these two drugs accounted for 56% of the company's sales, creating a heavy reliance on their continued success for future revenue.
- Patent Risks and Market Challenges: The limited patent protection period for new drugs poses a significant risk, as generic alternatives will enter the market post-patent expiration, leading to a sharp decline in sales, thus Eli Lilly faces the looming threat of a patent cliff.
- Strategic Investments and Acquisitions: To mitigate the patent cliff risk associated with GLP-1 drugs, Eli Lilly is leveraging its GLP-1 revenue to invest in new opportunities, partnering with Seamless Therapeutics for gene editing technology and acquiring Ventyx Biosciences for oral inflammation treatments, reflecting its strategic intent for diversified investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1008.390
Low
950.00
Averages
1192
High
1500
Current: 1008.390
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lilly's Remarks on the CMMI Balance Model for GLP-1 Medications
Statement Overview: Lilly's statement addresses the balance model for GLP-1 medicines, emphasizing its importance in the context of healthcare and patient outcomes.
Focus on GLP-1 Medicines: The statement highlights the role of GLP-1 medicines in managing conditions such as diabetes and obesity, underlining their therapeutic benefits.
Commitment to Innovation: Lilly reaffirms its commitment to innovation in the pharmaceutical industry, aiming to enhance treatment options and improve patient care.
Call for Collaboration: The statement encourages collaboration among stakeholders to optimize the use of GLP-1 medicines and ensure equitable access for patients.
See More
Eli Lilly's Medicare Drug Costs May Exceed $50 Cap
- Cost Cap Concerns: Eli Lilly has indicated that some Medicare enrollees may face out-of-pocket costs exceeding the $50 cap for its weight loss and obesity drugs, potentially impacting patient access and the company's competitive position in the market.
- New Payment Model: The BALANCE model introduced by the Centers for Medicare & Medicaid Services (CMS) aims to lower costs for GLP-1 drugs, set to take effect in 2027, which may influence Eli Lilly's sales strategies and market share.
- Patient Education Initiatives: Lilly stated it will actively educate patients and their physicians about plan options and smoothing programs to help patients access medications at the lowest possible out-of-pocket costs, reflecting the company's commitment to patient support and potentially affecting its brand image.
- Increased Market Competition: As CMS negotiates directly with GLP-1 drug manufacturers, Lilly may face pressure from competitors like Novo Nordisk, impacting its leadership position in the obesity drug market.
See More
Samsung Biologics Partners with Eli Lilly to Establish Gateway Labs in Korea
- Collaboration Agreement: Samsung Biologics has signed a collaboration agreement with Eli Lilly to establish Lilly Gateway Labs in Korea, aimed at supporting early-stage and emerging biotech companies while fostering collaboration and innovation in the Korean life sciences sector.
- Facility Development: Under the agreement, Samsung Biologics will develop and operate the new facility, with Lilly Gateway Labs providing customized scientific support to accelerate the growth of resident biotech companies.
- Ecosystem Contribution: The lab is expected to attract global innovation activities and foster talent development, thereby strengthening Korea's position as a hub for early-stage life science research and enhancing the overall biotechnology ecosystem in the country.
- Project Timeline: The new facility is expected to be completed by July 2027, and Samsung's stock closed up 0.82% at KRW 1,592,000 on the Korea Stock Exchange, reflecting positive market sentiment towards this collaboration.
See More
Market Update: Oil Price Drop and Tech Stock Upgrades
- Oil Price Fluctuations: U.S. benchmark WTI crude prices have fallen below $90 a barrel, despite being up over 50% year-to-date, indicating market optimism regarding improved U.S.-Iran relations, yet geopolitical risks continue to loom over oil prices.
- Tech Stock Rating Changes: Intuit was upgraded to buy from hold by Rothschild & Co Redburn, with its stock rising over 30% since late February, although it remains down 28.5% for the year, reflecting a recovery in market confidence in its software products.
- Cybersecurity Stock Bounce: Morgan Stanley upgraded CrowdStrike from hold to buy, with its stock up over 20% from last month's low, highlighting the positive impact of AI technology on the cybersecurity sector and indicating optimistic market expectations for future growth.
- Hewlett Packard Enterprise's Positive Outlook: Despite memory cost pressures, the company raised its full-year earnings outlook, with reported quarterly revenues slightly below expectations but gross margins and adjusted EPS exceeding forecasts, demonstrating strong demand in the data center buildout.
See More
Eli Lilly Stock Faces Pressure Amid Market Concerns
- Stock Decline: Eli Lilly's stock has fallen by 8% year-to-date, and while it boasts a five-year gain of approximately 380%, there is waning excitement around it and other GLP-1 stocks, reflecting broader pressures in the healthcare sector to reduce prices.
- High Valuation: Currently trading at a price-to-earnings ratio of 43, significantly above the S&P 500 average of 25, investors must weigh whether such a premium is justified or if waiting for a lower entry point is more prudent.
- Analyst Optimism: Despite the stock's decline, analysts maintain a positive outlook, with a consensus price target just under $1,230, suggesting a potential upside of around 24% over the next year, indicating sustained market appetite for the stock.
- Strong Performance: Eli Lilly's business has thrived due to the success of its GLP-1 drugs, Zepbound and Mounjaro, with last year's revenue exceeding $65 billion, marking a 45% increase from the previous year, solidifying its status as the most valuable healthcare company globally.
See More
Novo Nordisk Plans Major Price Cuts for GLP-1 Drugs
- Pricing Strategy: Starting in 2027, Novo Nordisk plans to reduce the list price of its GLP-1 drugs to $675 per month, representing a potential 50% cut, which will make treatments more accessible for high-deductible patients and could enhance market share.
- Competitive Pressure: In response to competition from Eli Lilly, whose Zepbound drug shows superior weight loss results, Novo Nordisk's pricing strategy aims to maintain its competitive edge in the weight loss market, particularly as Zepbound's price is slightly lower than Wegovy's.
- Profit vs. Market Share: While price reductions may impact short-term profits, Novo Nordisk maintains a gross margin of 80.9%, allowing the company to sacrifice some profit to capture market share, which is crucial for long-term growth.
- Investor Confidence: Should the pricing strategy lead to stronger growth prospects, Novo Nordisk's stock, currently trading at less than 11 times its trailing earnings, could be viewed as undervalued, attracting growth-focused investors.
See More
Lilly's Remarks on the CMMI Balance Model for GLP-1 Medications
Statement Overview: Lilly's statement addresses the balance model for GLP-1 medicines, emphasizing its importance in the context of healthcare and patient outcomes.
Focus on GLP-1 Medicines: The statement highlights the role of GLP-1 medicines in managing conditions such as diabetes and obesity, underlining their therapeutic benefits.
Commitment to Innovation: Lilly reaffirms its commitment to innovation in the pharmaceutical industry, aiming to enhance treatment options and improve patient care.
Call for Collaboration: The statement encourages collaboration among stakeholders to optimize the use of GLP-1 medicines and ensure equitable access for patients.
See More
Eli Lilly's Medicare Drug Costs May Exceed $50 Cap
- Cost Cap Concerns: Eli Lilly has indicated that some Medicare enrollees may face out-of-pocket costs exceeding the $50 cap for its weight loss and obesity drugs, potentially impacting patient access and the company's competitive position in the market.
- New Payment Model: The BALANCE model introduced by the Centers for Medicare & Medicaid Services (CMS) aims to lower costs for GLP-1 drugs, set to take effect in 2027, which may influence Eli Lilly's sales strategies and market share.
- Patient Education Initiatives: Lilly stated it will actively educate patients and their physicians about plan options and smoothing programs to help patients access medications at the lowest possible out-of-pocket costs, reflecting the company's commitment to patient support and potentially affecting its brand image.
- Increased Market Competition: As CMS negotiates directly with GLP-1 drug manufacturers, Lilly may face pressure from competitors like Novo Nordisk, impacting its leadership position in the obesity drug market.
See More
Samsung Biologics Partners with Eli Lilly to Establish Gateway Labs in Korea
- Collaboration Agreement: Samsung Biologics has signed a collaboration agreement with Eli Lilly to establish Lilly Gateway Labs in Korea, aimed at supporting early-stage and emerging biotech companies while fostering collaboration and innovation in the Korean life sciences sector.
- Facility Development: Under the agreement, Samsung Biologics will develop and operate the new facility, with Lilly Gateway Labs providing customized scientific support to accelerate the growth of resident biotech companies.
- Ecosystem Contribution: The lab is expected to attract global innovation activities and foster talent development, thereby strengthening Korea's position as a hub for early-stage life science research and enhancing the overall biotechnology ecosystem in the country.
- Project Timeline: The new facility is expected to be completed by July 2027, and Samsung's stock closed up 0.82% at KRW 1,592,000 on the Korea Stock Exchange, reflecting positive market sentiment towards this collaboration.
See More
Market Update: Oil Price Drop and Tech Stock Upgrades
- Oil Price Fluctuations: U.S. benchmark WTI crude prices have fallen below $90 a barrel, despite being up over 50% year-to-date, indicating market optimism regarding improved U.S.-Iran relations, yet geopolitical risks continue to loom over oil prices.
- Tech Stock Rating Changes: Intuit was upgraded to buy from hold by Rothschild & Co Redburn, with its stock rising over 30% since late February, although it remains down 28.5% for the year, reflecting a recovery in market confidence in its software products.
- Cybersecurity Stock Bounce: Morgan Stanley upgraded CrowdStrike from hold to buy, with its stock up over 20% from last month's low, highlighting the positive impact of AI technology on the cybersecurity sector and indicating optimistic market expectations for future growth.
- Hewlett Packard Enterprise's Positive Outlook: Despite memory cost pressures, the company raised its full-year earnings outlook, with reported quarterly revenues slightly below expectations but gross margins and adjusted EPS exceeding forecasts, demonstrating strong demand in the data center buildout.
See More
Eli Lilly Stock Faces Pressure Amid Market Concerns
- Stock Decline: Eli Lilly's stock has fallen by 8% year-to-date, and while it boasts a five-year gain of approximately 380%, there is waning excitement around it and other GLP-1 stocks, reflecting broader pressures in the healthcare sector to reduce prices.
- High Valuation: Currently trading at a price-to-earnings ratio of 43, significantly above the S&P 500 average of 25, investors must weigh whether such a premium is justified or if waiting for a lower entry point is more prudent.
- Analyst Optimism: Despite the stock's decline, analysts maintain a positive outlook, with a consensus price target just under $1,230, suggesting a potential upside of around 24% over the next year, indicating sustained market appetite for the stock.
- Strong Performance: Eli Lilly's business has thrived due to the success of its GLP-1 drugs, Zepbound and Mounjaro, with last year's revenue exceeding $65 billion, marking a 45% increase from the previous year, solidifying its status as the most valuable healthcare company globally.
See More
Novo Nordisk Plans Major Price Cuts for GLP-1 Drugs
- Pricing Strategy: Starting in 2027, Novo Nordisk plans to reduce the list price of its GLP-1 drugs to $675 per month, representing a potential 50% cut, which will make treatments more accessible for high-deductible patients and could enhance market share.
- Competitive Pressure: In response to competition from Eli Lilly, whose Zepbound drug shows superior weight loss results, Novo Nordisk's pricing strategy aims to maintain its competitive edge in the weight loss market, particularly as Zepbound's price is slightly lower than Wegovy's.
- Profit vs. Market Share: While price reductions may impact short-term profits, Novo Nordisk maintains a gross margin of 80.9%, allowing the company to sacrifice some profit to capture market share, which is crucial for long-term growth.
- Investor Confidence: Should the pricing strategy lead to stronger growth prospects, Novo Nordisk's stock, currently trading at less than 11 times its trailing earnings, could be viewed as undervalued, attracting growth-focused investors.
See More
